Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented): A compound of Formula (I):



(I)

wherein R^1 represents H, halogen, or a group -YZ;

Y represents a bond (i.e. is absent), C_{1-6} alkylene or C_{2-6} alkenylene;

Z represents an aryl or heteroaryl group each comprising 5-14 ring members, said aryl or heteroaryl being optionally substituted by one or more substituents independently selected from halogen, OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, CN, C_{1-6} hydroxyalkyl, phenyl, O-$(CH_2)_{1-6}$-phenyl, $NHSO_2R^3$, $NHCOR^3$, $CONR^4R^5$, $SO_2NR^4R^5$;

R^3, R^4 and R^5 independently represent H or C_{1-6} alkyl;

R^2 represents a group $-Y^1Z^1$;
Y^1 represents a bond (i.e. is absent), C_{1-6} alkylene, C_{2-6} alkenylene;

Z^1 represents a 6 membered heterocycle which is 4-piperidyl which may be optionally substituted by one or more substituents independently selected from SO_2R^6, $NHSO_2R^6$, 

, COR^7, NR^7R^8, $SO_2NR^7R^8$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, $CONR^7R^8$, $NHCOR^7$, or phenyl (directly attached or attached by a C_{1-6}alkylene, CONH, C_{2-6} alkenylene spacer

and optionally-substituted by one or more substituent selected from  , C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, OH, halogen);

R^6 represents H, C_{1-6} alkyl, $-(CH_2)_n$ phenyl or $-(CH_2)_n$ napthyl (where n is 0 or 1 and each of which phenyl or naphthyl may be optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, NR^7R^8, C_{1-6} haloalkyl, C_{1-6} haloalkoxy), CN or $-(O)_p$ phenyl (where p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, C_{1-6} alkyl or C_{1-6} alkoxy));

R^7 and R^8 independently represents C_{1-6} alkyl, H, C_{1-6} alkylene NR^9R^{10}; and

R^9 and R^{10} independently represents C_{1-6} alkyl, H;

or a pharmaceutically acceptable salt thereof.

2. (Original): A compound according to claim 1 wherein R^1 is YZ.

3. (Original): A compound according to claim 2 wherein Y is a bond or –CH = CH-.

4. (Original): A compound according to claim 3 wherein Y is a bond.

5. (Previously presented): A compound according to claim 1 wherein Z is phenyl (which may be unsubstituted or substituted once or twice by substituents independently selected from C_{1-3} alkoxy, CN, OH, phenyl, $-OCH_2$ phenyl $NHSO_2R^3$, $NHCOR^3$, $CONR^4R^5$, $SO_2NR^4R^5$, halogen, C_{1-3} hydroxyalkyl, C_{1-4} alkyl) or a heteroaryl group selected from benzofuranyl, quinolinyl,  , pyrimidinyl, thiophenyl, isoxazolyl, pyridinyl (each of which may be optionally substituted by one or two groups independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, halogen.

6. (Original): A compound according to claim 5 wherein Z is phenyl (which is unsubstituted or substituted once by a substituent selected from phenyl, OCH_2 phenyl, $NHSO_2CH_3$, $NHCOCH_3$, $CONH_2$, $CON(CH_3)_2$, Cl, F, OCH_3, CN, OH, CH_2OH, CH_3, $C(CH_3)_3$) or a heterocyclic group selected

from benzofuranyl, quinolinyl,  , pyrimidinyl, thiophenyl, benzothiophenyl, isoxazolyl, pyridinyl (each of which is substituted or is substituted once by a group selected from -OCH_3, CH_3, F).

7. (Original): A compound according to claim 6 wherein Z is phenyl (which is unsubstituted or substituted once by a substituent selected from phenyl, OCH_2 phenyl, $NHSO_2CH_3$, $NHCOCH_3$, $CONH_2$, $CON(CH_3)_2$, Cl, F, OCH_3, CN, OH, CH_2OH, CH_3, $C(CH_3)_3$).

8. (Original): A compound according to claim 7 wherein Z is phenyl.

Claims 9-10 (Cancelled)

11. (Previously presented): A compound according to claim 1, wherein Y^1 is a bond or C_{1-3} alkylene.

12. (Withdrawn): A compound according to claim 10 wherein Z^1 is phenyl (unsubstituted or substituted by one substituent selected from $NHSO_2R^6$, $CONR^7R^8$, CF_3, C_{1-3} alkoxy, SO_2R^6, $NHCOR^7$, $SO_2NR^7R^8$, NR^7R^8) or a 6 membered heterocyclic group which contains one nitrogen atom (which is unsubstituted or substituted one time by a group selected from C_{1-3} alkyl, CH_2 phenyl, SO_2R^6, $CONR^7R^8$).

13. (Previously presented): A compound according to claim 1, wherein Z^1 is a 6 membered heterocycle which is 4-piperidyl substituted by SO_2R^6.

Claims 14-18 (Cancelled)

19. (Previously presented): A pharmaceutical composition, comprising a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

Claims 20-22 (Cancelled)

23. (Withdrawn): A method of treating a disorder in a mammal, said disorder being mediated by inappropriate kinase activity, comprising administering to said mammal a compound as claimed in claim 1, or a salt, solvate, or a physiologically functional derivative thereof.

24. (Withdrawn): A method according to claim 23 wherein the inappropriate kinase activity is inappropriate IKK2 activity.

25. (Withdrawn): A method according to claim 24 wherein the disorder mediated by inappropriate IKK2 activity is inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease); osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage; autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restonosis, diabetes, glomerulonephritis, cancer, including Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiestasia, comprising administering a therapeutically effective amount to a mammal of a compound of formula (I), or a salt, solvate or pharmaceutically functional derivative thereof.

Claims 26-38 (Cancelled)

39. (New): A method of treating a disorder in a mammal, said disorder being mediated by inappropriate kinase activity, comprising administering to said mammal a compound as claimed in claim 1.

40. (New): A method according to claim 39 wherein the inappropriate kinase activity is inappropriate IKK2 activity.

41. (New): A method according to claim 40 wherein the disorder mediated by inappropriate IKK2 activity is inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease); osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage; autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection,

Alzheimer's disease, stroke, atherosclerosis, restonosis, diabetes, glomerulonephritis, cancer, including Hodgkin’s disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiestasia, comprising administering a therapeutically effective amount to a mammal of a compound of formula (I), or a salt, solvate or pharmaceutically functional derivative thereof.